Cybin Inc. (R7E1.F)

0,3200 0,0000 (0,00%) Ab 08:11AM CEST. Markt geöffnet.

Cybin Inc.

100 King Street West
Suite 5600
Toronto, ON M5X 1C9
Canada

https://www.cybin.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 50

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Eric So L.L.B.	Co-Founder, President & Executive Chairman	426,75k	N/A	1976
Mr. Douglas L. Drysdale	Chief Executive Officer	570,49k	N/A	1970
Mr. Paul Glavine	Co-Founder, Chief Growth Officer & Director	426,75k	N/A	1989
Mr. Greg Cavers	Chief Financial Officer	225,14k	N/A	1971
Mr. Aaron Bartlone	Chief Operating Officer	352,57k	N/A	N/A
Mr. John Kanakis	Co-Founder	654,74k	N/A	1980
Dr. Alex L. Nivorozhkin Ph.D.	Chief Scientific Officer	N/A	N/A	1960
Ms. Lori Challenger	Chief Compliance, Ethics & Administrative Officer	N/A	N/A	N/A
Mr. Gabriel Fahel	Chief Legal Officer & Corporate Secretary	N/A	N/A	1976
Sara Brittany Somerset	Chief Communications Officers	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Corporate Governance

Cybin Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.